Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

How the U.S. government bolstered Moderna’s COVID-19 vaccine candidate

By Brian Buntz | November 23, 2020

Coronavirus vaccine

[Image courtesy of Wikipedia]

Until recently, the most rapidly developed vaccine was for mumps, which took four years. Now, Pfizer (NYSE:PFE) and Moderna (NSDQ:MRNA) appear to be on the cusp of commercializing COVID-19 vaccines under emergency use authorization.

It was only a year ago that physicians in China identified unusual pneumonia cases that would later be associated with the novel coronavirus.

As impressive as the rapid pace of COVID-19 vaccine development has been, researchers have drawn on foundational work that stretches back almost two decades, said Barry Bloom, a research professor at Harvard University, in the recent webinar titled the “Race for the COVID-19 Vaccine: Latest Updates.”

And the Moderna vaccine candidate, in particular, has benefited from U.S. government support.

A marathon as well as a sprint

The race to develop COVID vaccines has roots stretching back to the terrorist attacks on September 11 and the anthrax attacks that followed in the subsequent weeks. The events led the National Academy of Sciences to convene a set of committees to examine the twin threats of terrorism and pandemics. The committees “concluded that we were enormously vulnerable and we had to do a lot of different things [to] protect the country,” said Bloom, who co-chaired a bioterrorism panel for the National Academy of Sciences at the time.

In 2002, severe acute respiratory syndrome (SARS) first appeared in China and took hold internationally within months. Effective public health interventions prevented SARS from becoming a pandemic.

In 2005, the U.S. Department of Health and Human Services (HHS) established the National Pandemic Influenza Plan to provide a blueprint for pandemic response. “At some point in our nation’s future, another virus will emerge with the potential to create a global disease outbreak,” Health and Human Services Secretary Mike Leavitt at the time.

The pandemic plan stressed the importance of antiviral drugs and vaccines. “It is a wonderful plan,” Bloom noted. But before COVID-19 hit, the report had “disappeared in a drawer somewhere in Washington,” he added.

But the U.S. government’s focus on vaccines to combat pandemics likely played a role in spurring further research into novel vaccine platforms.

DARPA and BARDA make vaccine investments

Government agencies such as the Defense Advanced Research Projects Agency (DARPA) and the Biomedical Advanced Research and Development Authority (BARDA) would play a role in vaccine development. DARPA “invests in very long term science and technology [projects] that will pay off in 20 years,” Bloom said.

The National Institute of Allergy and Infectious Diseases (NIAID) developed a stabilized SARS-CoV-2 spike immunogen (S-2P) that Moderna would later use in its messenger RNA platform.

DARPA was instrumental in the development of RNA vaccines and provided $25 million in financial support to Moderna in 2013 to pursue messenger RNA–based antibody drugs and vaccines. DARPA announced it was committing up to $56 million in additional funding to Moderna this October.

BARDA has committed another roughly $955 million to Moderna.

In all, the U.S. government vaccine contract with Moderna is worth roughly $1.5 billion. BARDA has also invested in producers of other COVID-19 vaccines.

BARDA was also instrumental in resetting researchers’ expectations for vaccine development, Bloom said. The organization set a goal of developing a vaccine 60 days after determining a pathogen’s DNA sequence. Moderna had a vaccine candidate 66 days after scientists identified its genetic sequence. “And that is a reflection of tremendous foresight by these technical agencies,” Bloom said. By identifying promising research and identifying companies to advance it, the government agencies have played a role in engineering COVID-19 vaccines. But the platform approach could also help fight future pandemics, given its ability to allow researchers to tweak antigens and genes to target a new pathogen.

The U.S. government’s support of the vaccine platform led to investigations into its use to treat infections from Middle East Respiratory Syndrome (MERS), influenza, Zika and HIV. “We had a background on these vaccines,” Bloom said. “The companies were pretty confident they would work [for the novel coronavirus], but it will take [trials] to find out how safe and effective for COVID they really are.”


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, HHS, Moderna, National Institutes of Health, Pfizer
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Comments

  1. Jsg says

    March 13, 2021 at 4:01 am

    Thank you. It’s nice to get the real story, when the ex president thinks he deserves all the credit.

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE